Circulating stem cell collection in lymphoma and myeloma after mobilization with cyclophosphamide and granulocyte colony-stimulating factor for autologous transplantation.
We report the results of 72 leukapheresis procedures performed for autologous peripheral blood stem cell collection in 18 patients with lymphoma and myeloma, after combined mobilization with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF). The numbers of mononuclear cells (MNCs), CD34+ cells and granulocyte-macrophage colony-forming units (CFU-GM) either in the peripheral circulation (preleukapheresis sample) or in the product obtained from leukapheresis (leukapheresis sample) were evaluated. A highly superior proportion of CD34+ cells (14-fold) and CFU-GM (5-fold) resulted from the mobilization therapy. CFU-GM and CD34+ cells were highly enriched with respect to all MNCs (relative recoveries: 2.13, range 0.3-41, and 1.08, range 0.2-8.5, respectively) due to an additional mobilization effect by the leukapheresis procedure. Also, a relatively strong linear correlation between the three different parameters was found in the leukapheresis product (CD34+:CFU-GM, r = 0.81; MNCs:CD34, r = 0.69; MNCs:CFU-GM, r = 0.75; CFU-GM:CD34+, and MNCs, r = 0.85). Our data suggest that the number of MNCs and CD34+ cells obtained after combined mobilization with cyclophosphamide and G-CSF can be used as predictor of the number of granulomonocytic progenitors.
Cancelas
J A
JA
Department of Haematology, Hospital Ramón y Cajal, Madrid, Spain.
Hernández-Jodra
M
M
Zamora
C
C
Perez-Oteyza
J
J
Brieva
J A
JA
Roldan
E
E
Navas
G
G
Garcia-Laraña
J
J
Lopez
J
J
Odriozola
J
J
D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34; D001773:Blood Cells; D002469:Cell Separation / Q000379:methods*; D003520:Cyclophosphamide / Q000494:pharmacology*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006689:Hodgkin Disease / Q000097:blood / Q000628:therapy; D006801:Humans; D007937:Leukapheresis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008223:Lymphoma / Q000097:blood* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000628:therapy; D009101:Multiple Myeloma / Q000097:blood* / Q000628:therapy
D015703:Antigens, CD; D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide